-
Nature: The absence of histone H1 destroys the chromatin 3D structure and drives the development of lymphoma
Time of Update: 2020-12-24
these changes unlock the expression of stem cell genes, which are usually silenced during early development.
, the study's data suggest that the H1 protein usually needs to seal early-development genes into structurally inconsequencable genomic compartments.
-
Blood: New CRBN E3 connective enzyme regulator CC-90009, targeted to promote leukemia stem cell apoptosis
Time of Update: 2020-12-24
AML activity of CC-90009 is regulated by ilF2/ILF3 complex, mTOR signal path and integrated stress response path.
many clinically effective drugs have been developed by re-using the CUL4-DDB1-CRBN-RBX1 (CRL4CRBN) E3 Ubigan connective enzyme complex with molecular gel degradation agents to eliminate pathogenic proteins.
-
Blood: IL-18 mediates the occurrence of sickle cell cardiomyopathy and cytocardiac titration
Time of Update: 2020-12-24
expression of the IL18 gene was enhanced in patients with myocardial fibrosis or QTc-enhanced SCD, and QTc was closely related to plasma IL-18 levels.
-
FDA approves Takeda's ICLUSIG (ponatinib) treatment for drug-resistant or drug-resistant chronic granulocytic leukemia
Time of Update: 2020-12-22
. Takeda Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved ICUSIG® (ponatinib) to treat patients with chronic granulocytic leukemia (CML) who are resistant to kinase inhibitors or are resistant to drugs.
-
The FDA has refused to approve Novaral's siRNA drug inclisiran
Time of Update: 2020-12-22
Pharmaceuticals said Friday that the FDA has issued a full response letter (CRL) to its marketing application for inclisiran, a siRNA drug for PCSK9, which is expected to be used to treat hyperlipidemia in adults with elevated LDL-cholesterol.
-
Soft chairs sit too long, more prone to hemorrhoids! Prevent hemorrhoids and change to a hard chair
Time of Update: 2020-12-22
when we sit in a soft chair for a long time, blood flow to the abdomen and lower extremities slows down and is blocked, and rectal varicose veins are easily varicose, leading to bruising, veins, and eventually hemorrhoids.
-
Lancet haematol: Is Dabiga esters expected to replace standard treatment for children with venous thrombosis?
Time of Update: 2020-12-22
The efficacy and safety of standard care (low molecular weight heparin, common heparin, vitamin K antagonists or sulfonda heparin) and oral dabiga esters in children under 18 years of age who require at least 3 months of anticoagulant therapy (5-21 days).
-
ASH 2020: The long-term efficacy and tolerance of Calquence's treatment of MCL
Time of Update: 2020-12-17
the median non-progressive survival of patients treated with calabrutinib (MCL) with recurring or refractic heterocytic lymphoma (MCL) continued for 22 months, based on long-term follow-up.
follow-up for 38.1 months, and 44% of patients continued to receive treatment.
-
"False heart failure"? 81-year-old grandmother "engine" failed, the original blood has this disease!
Time of Update: 2020-12-17
The 81-year-old grandmother suffered a "strange illness" "Thank you doctor." " October 14, Grandma Sun, accompanied by her son Mr. Li (analyte), came to jiang hospital area of Zhejiang University Hospital and walked into the specialist outpatient review of Dr. Yan Hui, director of cardiovascular medicine.
-
Blood: UTX maintains hemastation by regulating gene expression associated with aging
Time of Update: 2020-12-17
Utx gene defect (Utx-x/ut) mice showed poor bone marrow skewed with stunting, impaired hema production outside myelin, impaired hema production and reconstruction, and increased susceptivity to leukemia, all of which are characteristics of hema production aging.
-
ASH 2020: Anti-CD117 monoclonal antibody JSP191 for the treatment of severe combined immunodeficiency disease (SCID)
Time of Update: 2020-12-17
data from an unployed SCID patient (a 6-month-old baby) in a Phase I trial show that single dose of JSP191 before stem cell transplantation can effectively establish continuous supply chimosa.
-
Inventory: A selection of Blod research on December 3, 2020
Time of Update: 2020-12-17
: Study on the mechanism of glucosal hormone-induced eosinophil reduction https://doi.org/10.1182/blood.2020005161 Glucosteroids is considered a first-line drug for the treatment of various eosinophil diseases.
-
ASH 2020: Momelotinib treated patients with low plate counts with medium/high risk bone marrow fibrosis, who had positive results
Time of Update: 2020-12-17
about half of primary bone marrow fibrosis patients have a mutation in the Janus Kinase 2 (JAK2) gene.
in some patients, bone marrow fibrosis rapidly leads to anemia, decreased plate plate levels in the blood (plate plate reduction) or leukemia.
-
ASH 2020: Lilly's LOXO-305 shows a 62% mitigation rate in relapse-difficult CLL/SLL
Time of Update: 2020-12-17
Lilly recently released the latest results from the Phase I/II Clinical Trials (BRUIN Study), which evaluated the effectiveness of the non-co-priced BTK inhibitor LOXO-305 in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
-
Venecla, the world's first listed BCL-2 inhibitor, was approved in China
Time of Update: 2020-12-17
On January 13th Venetoclax, the selective inhibitor of AbbVie Bcl-2, the only apoptosis drug approved for sale in the world based on apoptosis mechanisms, was declared available in China.
-
Cell Death Dis:lncRNA HOXA-AS2 promotes the development of AML by binding EZH2 and inhibiting LATS2
Time of Update: 2020-12-17
previous studies have shown that lncRNA HOXA-AS2 plays an important role as a carcinogen in many tumors, but little is known about its role in AML.
silence HOXA-AS2 inhibits the proliferation of AML cells and induces their differentiation, while over-expression OFSA-AS2 shows the opposite result.
-
Blood: The IDH1 mutation causes myelin dysplate by interfering with hemolybin synthesis and red blood cell production
Time of Update: 2020-12-17
In the red-line cells of these mice, the abnormal metabolite D-2-hydroxypropyt acid (D-2HG) produced by the mutant IDH1 enzyme inhibited the activity of the oxygendic acid dehydrogenase (OGDH), thereby reducing the production of amberyl coenzyme A.
-
ESC 2020 online interview with Professor Dominick Angioliio, Single Antiplatellite Therapy: Insights into Early Use
Time of Update: 2020-12-17
In particular, recent studies have highlighted early single antiplate plate plate treatment in PCI patients, and to explore this issue, we brought in Professor Dominick Angioliio of the University of Florida School of Medicine to answer questions.
-
Blood: Erutini, Obinutuzumab and Venotclax combined to treat relapse/primary treatment of myoblastoma
Time of Update: 2020-12-17
OASIS (NCT02558816) is a one-arm, multi-center Phase I/II prospective trial designed to determine maximum tolerance (MTD) for patients with a combined fixed dose of venotclax erutinib and obinutuzumab to treat relapsed MCLs.
patients with relapsed/primary treatment MCL were treated with the largest to-1otclax static drops in the extended queue.
-
Blood: Will Bruton tyrosine kinase inhibitors affect the effectiveness of vaccination?
Time of Update: 2020-12-17
, BTKis therapy may weaken the effect of the head-on immune response after hepB-CpG vaccination, while BTKi therapy has no significant effect on the reimmune response after RZV.
